PT  - JOURNAL ARTICLE
AU  - Weibel, Stephanie
AU  - Popp, Maria
AU  - Reis, Stefanie
AU  - Skoetz, Nicole
AU  - Garner, Paul
AU  - Sydenham, Emma
TI  - Identifying and managing problematic trials: a Research Integrity Assessment (RIA) tool for randomized controlled trials in evidence synthesis
AID  - 10.1101/2022.05.31.22275756
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.05.31.22275756
4099  - http://medrxiv.org/content/early/2022/06/05/2022.05.31.22275756.short
4100  - http://medrxiv.org/content/early/2022/06/05/2022.05.31.22275756.full
AB  - Evidence synthesis findings depend on the assumption that the included studies follow good clinical practice and results are not fabricated or contain errors. Studies which are problematic due to scientific misconduct, poor research practice, or honest error may distort evidence synthesis findings. Authors of evidence synthesis need transparent mechanisms to identify and manage problematic studies to avoid misleading findings.As evidence synthesis authors of the Cochrane COVID-19 review on ivermectin, we identified many problematic studies in terms of research integrity and regulatory compliance. Through iterative discussion, we developed a Research Integrity Assessment (RIA) tool for randomized controlled trials (RCTs). RIA was piloted and used in updating this Cochrane review. In this paper, we explain the rationale and application of the RIA tool.RIA assesses six study criteria: study retraction, prospective trial registration, adequate ethics approval, plausible authorship, sufficient reporting of methods (e.g., randomization), and plausibility of study results. RIA was used in the Cochrane review as part of the eligibility check during screening of potentially eligible studies. Problematic studies were excluded and studies with open questions were held in awaiting classification until clarified. RIA decisions were made independently by two authors and reported transparently. Using the RIA tool resulted in the exclusion of >40% of studies in the first update of the review.RIA is a complementary tool prior to assessing ‘Risk of Bias’ aiming to establish the integrity and authenticity of studies. RIA provides a platform for urgent development of a standard approach to identifying and managing problematic studies.Competing Interest StatementThe authors have declared no conflict of interest. The tool was developed by a group of content experts who were either Cochrane review authors (SW, MP, SR, NS) and / or otherwise involved in Cochrane (SW, NS, PG, ES). SW is Content Editor of Cochrane Anaesthesia. NS is joint Co-ordinating Editor of Cochrane Haematology. PG is Co-ordinating Editor of the Cochrane Infectious Diseases Group and responsible for assuring quality of reviews. ES is Co-ordinating Editor of the Cochrane Injuries Group and was a member of Cochrane scientific misconduct policy advisory group.Funding StatementThe Federal Ministry of Education and Research, Germany, NaFoUniMedCovid19 (funding number: 01KX2021); part of the project "CEOsys" supported this work (funding ended 31 December 2021). SW received a bursary for updating the Cochrane ivermectin review from the National Center for Complementary and Integrative Health (NCCIH), USA (Grant Number R24 AT001293; Cochrane Complementary Medicine Field 2021). The funders had no role in considering the study design or in the collection, analysis, interpretation of data, writing of the report, or decision to submit the article for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data relevant to the study are included in the article, uploaded as supporting information, or available in the Cochrane ivermectin review with link to a public, open access repository.